Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors.

@article{Vasudevachari1992PreventionOT,
  title={Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors.},
  author={M. Vasudevachari and C. Battista and H. Lane and M. Psallidopoulos and B. Zhao and J. Cook and J. Palmer and D. Romero and W. G. Tarpley and N. Salzman},
  journal={Virology},
  year={1992},
  volume={190 1},
  pages={
          269-77
        }
}
Certain bisheteroarylpiperazines (BHAPs) directly inhibit the replication of human immunodeficiency virus type 1 (HIV-1) and block the spread of infection to susceptible populations of cells. At a 1 microM concentration three analogs, U-87201, U-88204, and U-89674, inhibited the replication of HIV-1 in MT-2 cells by 83, 100, and 93%, respectively. At the same concentration, U-88204 completely inhibited replication of primary HIV-1 isolates in peripheral blood mononuclear cells. Replication of 3… Expand
U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication
TLDR
Although the RT amino acid substitutions K103N (lysine 103 to asparagine) and Y181C (tyrosine 181 to cysteine), which confer cross-resistance to several nonnucleoside inhibitors, also decrease the potency of U-90152, this drug retains significant activity against these mutant RTs in vitro. Expand
Clonal selection of HIV type 1 variants associated with resistance to foscarnet in vitro: confirmation by molecular evolutionary analysis.
TLDR
PFA in combination with other RT inhibitors is considered to be a feasible candidate for a convergent combined chemotherapy against HIV-1 in the treatment of patients with AIDS and related conditions. Expand
Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
TLDR
Analysis of mutants used to analyze calanolide A, 1H,3H-thiazolo[3,4-a]benzimidazole(4i), and the acyclic nucleoside analog 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine suggest that all three drugs interact with HIV-1 RT within the previously defined common binding site for nonnucleoside inhibitors. Expand
Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
TLDR
U-90152 in combination with 3'-azido-3'-deoxythymidine (AZT) or ddC synergistically inhibited the replication of a laboratory-adapted strain and a clinical isolate of HIV-1. Expand
Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.
TLDR
Data provide an in vitro basis for beneficial use of DLV in combinations with DDI and ZDV in HIV-1 infected patients and show additive or synergistic drug toxicity. Expand
Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720
The human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase (RT) inhibitor quinoxaline S-2720 showed a more-potent inhibitory effect on HIV-1-induced cytopathicity in CEM cellsExpand
Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication
TLDR
S-2720 belongs to a new class of RT inhibitors that bind differently to the RT than other known nonnucleoside RT inhibitors and deserves further evaluation to prove their potency as possible therapeutic agents for HIV-1 infection. Expand
Oxathiin Carboxanilide Derivatives: A Class of Non-Nucleoside HIV-1-Specific Reverse Transcriptase Inhibitors (NNRTIs) that are Active against Mutant HIV-1 Strains Resistant to other NNRTIs
TLDR
Findings should be taken into account when selecting suitable drug candidates for the treatment of HIV-1 infections, particularly those that have developed resistance to other non-nucleoside RT inhibitors (NNRTIs). Expand
Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
TLDR
The data suggest that the interaction of atevirdine with HIV-1 RT is different than that of other nonnucleoside RT inhibitors and that combinations of atEVirdine and zidovudine may be useful in patients with AIDS who have initially received monotherapy with zidvudine. Expand
Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
  • W. Freimuth
  • Biology, Medicine
  • Advances in experimental medicine and biology
  • 1996
TLDR
DLV has been well-tolerated in > 1,000 HIV-1 infected patients and the surrogate marker responses in clinical trials suggest that DLV has clinical synergy with ZDV +/- ddI as evidenced by a better and more sustained surrogate marker response when a subject is sensitive to or naive to the nucleoside RTI combined with DLV. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.
TLDR
Dipyridodiazepinones inhibition of HIV-1 replication in vitro as demonstrated by in situ hybridization, inhibition of protein p24 production, and the lack of syncytia formation in cultured human T cell lines and freshly isolated human peripheral blood lymphocytes. Expand
Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.
TLDR
A novel 6-substituted acyclouridine derivative, HEPT, has proved to be a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) in vitro. Expand
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
TLDR
The reproducible nature of these mutations should make it possible to develop rapid assays to predict zidovudine resistance by performing polymerase chain reaction amplification of nucleic acid from peripheral blood lymphocytes, thereby circumventing current lengthy HIV isolation and sensitivity testing. Expand
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
IN the search for compounds active against human immunodeficiency virus (HIV), we have found that members of a novel series of tetrahydro-imidazo[4,5,1-jk][l,4]-benzodiazepin-2(1H)-one and -thioneExpand
Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors.
Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), an important therapeutic target in the treatment of AIDS, is effectively inhibited by a class of nonnucleoside analog compoundsExpand
Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors
TLDR
Human immunodeficiency virus type 1 (HIV-1)-specific pyridinone reverse transcriptase (RT) inhibitors prevent HIV-1 replication in cell culture and may all make up a single pharmacologic class of RT inhibitor. Expand
Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity.
Derivatives of pyridinones were found to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity and prevent the spread of HIV-1 infection in cell culture without anExpand
Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.
  • P. Ashorn, B. Moss, +4 authors E. Berger
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1990
TLDR
Combination treatment can completely eliminate infectious HIV-1 from cultures of human T-cell lines and highlights the therapeutic potential of treatment regimens involving combination of a virostatic drug that inhibits virus replication plus an agent that selectively kills HIV-infected cells. Expand
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
TLDR
It would be premature to alter any treatment protocols for HIV-infected individuals at present, as it cannot be determined from this small sample of patients whether development of a less sensitive virus phenotype results in clinical resistance. Expand
Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.
TLDR
The levels of HIV-1 in plasma and PBMC are much higher than previous estimates, raising the possibility that the direct cytopathic effect of this retrovirus alone may be sufficient to explain much of the pathogenesis of AIDS. Expand
...
1
2
3
4
5
...